October 1981

Clinical Evaluation of Piperacillin Therapy for Infection

Author Affiliations

From the Division of Infectious Diseases, Departments of Medicine (Dr Pancoast, Francke, and Neu) and Pediatrics (Dr Prince), Columbia University College of Physicians and Surgeons, New York. Dr Pancoast is now at the Mercy and Moses-Taylor Hospital, Scranton, Pa. Dr Francke is now at Abbott-Northwestern Hospital, Minneapolis.

Arch Intern Med. 1981;141(11):1447-1450. doi:10.1001/archinte.1981.00340120055012

Piperacillin sodium, a semisynthetic penicillin that inhibits many Klebsiella and Pseudomonas aeruginosa organisms resistant to carbenicillin, was used to treat 41 episodes of infection in 35 patients. Infectious sites included lungs, urinary tract, and tissue, including peritonitis. Seven patients had bacteremia. Clinical and bacteriological cures were achieved in 85% of infections. Cure was achieved with piperacillin in patients infected with carbenicillin-resistant P aeruginosa and Klebsiella organisms. Adverse effects were minor and included rash in two patients. Serum levels were easily maintained above the inhibitory levels for susceptible organisms. Piperacillin was a safe, well-tolerated, and effective antimicrobial agent.

(Arch Intern Med 1981;141:1447-1450)